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Abstract
Context: Altered tissue-specific glucocorticoid metabolism has been described in uncomplicated obesity and type 2 
diabetes. We hypothesized that weight loss induced by diet and exercise, which has previously been shown to reverse 
abnormal cortisol metabolism in uncomplicated obesity, also normalizes cortisol metabolism in patients with type 2 
diabetes.
Objective: Test the effects of a diet intervention with added exercise on glucocorticoid metabolism.
Design: Two groups followed a Paleolithic diet (PD) for 12 weeks with added 180 min of structured aerobic and 
resistance exercise per week in one randomized group (PDEX).
Setting: Umeå University Hospital.
Participants: Men and women with type 2 diabetes treated with lifestyle modification ± metformin were included. 
Twenty-eight participants (PD, n = 15; PDEX, n = 13) completed measurements of glucocorticoid metabolism.
Main outcome measures: Changes in glucocorticoid metabolite levels in 24-h urine samples, expression of HSD11B1 
mRNA in s.c. adipose tissue and conversion of orally administered cortisone to cortisol measured in plasma. Body 
composition and insulin sensitivity were measured using a hyperinsulinemic-euglycemic clamp, and liver fat was 
measured by magnetic resonance spectroscopy.
Results: Both groups lost weight and improved insulin sensitivity. Conversion of orally taken cortisone to plasma 
cortisol and the ratio of 5α-THF + 5β-THF/THE in urine increased in both groups.
Conclusions: These interventions caused weight loss and improved insulin sensitivity with concomitant increases in the 
conversion of cortisone to cortisol, which is an estimate of hepatic HSD11B1 activity. This suggests that dysregulation 
of liver glucocorticoid metabolism in these patients is a consequence rather than a cause of metabolic dysfunction.
Introduction
Cushing’s syndrome, caused by overexposure of cortisol, 
is associated with abdominal adiposity, hypertension, 
dyslipidemia, insulin resistance and type 2 diabetes (1). 
This phenotype is strikingly similar to obesity and the 
metabolic syndrome. However, circulating cortisol levels 
are normal or slightly decreased in obese individuals (2), 
whereas studies suggest increased circulating cortisol 
levels in type 2 diabetes (3).
Circulating cortisol levels are regulated by the 
hypothalamic-pituitary-adrenal axis. Furthermore, cortisol 
exposure is regulated at the tissue level by a series of metabolic 
enzymes, with most attention paid to 11β hydroxysteroid 
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dehydrogenase type 1 (HSD11B1) which converts inactive 
cortisone to active cortisol and HSD11B2 which converts 
cortisol to cortisone. Notably, HSD11B1 activity in adipose 
tissue is increased in individuals with obesity (4, 5) and 
hepatic HSD11B1 activity is decreased (4). However, among 
obese individuals with type 2 diabetes, hepatic HSD11B1 
activity is sustained (6, 7). This is important since HSD11B1 
has been highlighted as a potential drug target in type 2 
diabetes (8).
The conversion of cortisone to cortisol by HSD11B1 
is regulated by several factors related to obesity and type 
2 diabetes (8). The increased expression of HSD11B1 
in s.c. adipose tissue has been associated with chronic 
inflammation (9), and treatment with anti-inflammatory 
salicylate decreases s.c. HSD11B1 expression in obese 
patients (10). The decreased activity of HSD11B1 in the 
liver among individuals with obesity has been suggested 
to be caused by chronic hyperinsulinemia, whereas the 
sustained hepatic HSD11B1 activity among patients with 
type 2 diabetes may be caused by insulin resistance and 
a relative insulin deficiency (6, 11, 12). Furthermore, 
increased liver fat has been associated with increased 
excretion of glucocorticoid (GC) metabolites in urine 
and decreased hepatic HSD11B1 activity (13, 14). The 
association between anthropometric measurements, 
insulin sensitivity and liver fat with tissue-specific GC 
metabolism has not been tested among patients with type 
2 diabetes.
Diet and exercise are fundamental components of 
the treatment of type 2 diabetes (15, 16). Among obese 
individuals without type 2 diabetes diet-induced weight 
loss has been associated with decreased excretion of 
GC metabolites in urine (17), decreased expression of 
HSD11B1 in adipose tissue (18) but unaltered hepatic 
HSD11B1 activity (17, 18). Notably, the effects of diet 
and exercise on tissue-specific GC metabolism have not 
been studied in patients with type 2 diabetes. Thus, it is 
currently unknown whether the benefits of weight loss 
and improved insulin sensitivity are associated with 
changes in tissue-specific GC metabolism.
The Paleolithic diet (PD) is considered to be a diet that 
humans have adapted to for thousands of years. Thus, 
the radical change in dietary intake during recent decades 
might explain the increased prevalence of obesity, type 2 
diabetes and cardiovascular disease (19, 20). The PD causes 
a greater weight loss than a conventional diet according 
to Nordic Nutrition Recommendations among obese 
women without type 2 diabetes (21). Furthermore, the PD 
has been shown to improve insulin sensitivity and reduce 
hepatic lipid levels among patients with type 2 diabetes 
(22, 23). In general, the PD excludes the intake of dairy 
products, salt, refined sugar and grains, while the intake of 
vegetables, lean meat, fish and nuts is increased (21, 22).
Adding exercise training to dietary changes increases 
the beneficial effects on anthropometric measures as 
well as insulin sensitivity and glucose control (24). 
Furthermore, combining resistance and aerobic exercise 
is associated with larger improvements in glucose control 
than either modality alone, among patients with type 
2 diabetes (16). The effect of adding exercise to dietary 
changes on tissue specific GC metabolism has not been 
tested in either individuals with obesity or patients with 
type 2 diabetes.
We aimed to (1.) test the association between 
anthropometric measurements, insulin sensitivity and 
liver fat with indices of tissue specific GC metabolism, 
(2.) test whether alterations in tissue specific GC 
metabolism can be reversed by weight-loss and associated 
improvements in insulin sensitivity and reduction in liver 
fat and (3.) test the additional effects of structured aerobic 
and resistance exercise to a PD on tissue specific GC 
metabolism in patients with type 2 diabetes. To achieve 
this we undertook analyses of secondary outcomes from 
an intervention trial for which the primary outcomes 
have already been published (22, 23).
Subjects and methods
Participants
Thirty-two weight-stable (<5% weight change last 
6 months), overweight or obese (BMI 25–40 kg/m2) 
subjects diagnosed with type 2 diabetes within 10 years 
and treated with lifestyle modification ± metformin were 
included in this study. All participants were sedentary and 
had thus performed less than 30 min of moderately intense 
physical activity 5 days per week or resistance exercise less 
than once every other week during the last 6 months. 
Eligible men were 30–70 years old and women were 
included after menopause up to 70 years of age to avoid 
interference of menopause and the menstrual cycle on 
measurements of tissue-specific GC metabolism (25, 26). 
Exclusion criteria included use of antidiabetic drugs other 
than metformin, ischemic heart disease, stroke, blood 
pressure >160/100 mmHg, use of beta-blockers, being a 
smoker and macroalbuminuria.
All participants provided written informed consent 
before inclusion. The study was approved by the Regional 
Ethical Review Board, Umeå, Sweden and was conducted 
in accord with the Helsinki Declaration.
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Interventions
Participants were randomized to a Paleolithic diet alone 
(PD) or combined with a supervised exercise intervention 
(PDEX). Sixteen participants were randomized to 
each group, and one participant in the PD group and 
two in the PDEX did not complete the interventions. 
Furthermore, one participant in the PDEX did not provide 
repeated measurements on any tests of tissue-specific 
GC metabolism and was therefore excluded from the 
final analysis. The study was single-blind such that all 
staff collecting and analysing data were blind to group 
allocation.
The Paleolithic type diet included recommendations 
of a high intake of vegetables, fruit, lean meat, nuts, egg, 
fish and seafood. The intake of grains, sugar, salt, dairy 
products and refined fats was reduced (for details see (22)). 
Each group participated separately in five group sessions 
with a trained dietician at the Department of Food and 
Nutrition, Umeå University. They were given information, 
recipes and were shown how to cook a Paleolithic type 
diet. The first two meetings were held during the first two 
weeks after baseline measurements and thereafter once 
a month. The participants could contact the dietician 
by phone or email between sessions. Four-days of self-
reported weighted food records at baseline and after 12 
weeks were used to estimate diet adherence.
Before randomization, all participants met individually 
with a physician and were given recommendations of 
performing at least 30 min of moderately intense physical 
activity, for example, a brisk walk, each day in line with 
diabetes guidelines (27). In addition, 16 participants 
were randomized to a structured high intensity exercise 
intervention, added to the moderately intense physical 
activity recommendation, including three 1-h exercise 
sessions per week for 12 weeks. The exercise consisted 
of aerobic and resistance exercise (50% each) performed 
under supervision of an educated personal trainer at the 
Sports Medicine Unit, Umeå University. For details please 
refer 22. A standardized cardiopulmonary exercise test 
was used to measure peak oxygen uptake before and after 
the interventions.
Body composition, anthropometric measures, liver 
fat and insulin sensitivity
Measurements were performed during a 3-week period 
before randomization and after the 12-week interventions. 
Weight was measured on a calibrated digital scale in 
light clothing, height was measured with a calibrated 
height-measuring gauge and waist circumference with 
a measuring tape midway between the iliac crest and 
lowest rib. Body composition was estimated with dual-
energy X-ray absorptiometry (Lunar Prodigy X-ray Tube 
housing Assembly, Brand BX-1 L, Model 8743; GE Medical 
Systems, Madison, WI, USA). HbA1c was analyzed using 
routine clinical methods at the Department for Clinical 
Chemistry, Umeå University Hospital. Fasting glucose 
was analyzed from a capillary sample (HemoCue 201 RT; 
Radiometer Medical Aps, Brønshøj, Denmark). Cortisol 
binding globulin (CBG) was measured in serum using a 
competitive RIA (DIAsource ImmunoAssays, Louvain – 
la – Neuve, Belgium). The hyperinsulinemic-euglycemic 
clamp technique combined with (6,6-2H2) glucose 
infusion was used to assess peripheral and hepatic insulin 
sensitivity as previously described (23). Ten participants 
in the PD group and 12 participants in the PDEX group 
who provided measures of GC metabolism completed 
the hyperinsulinemic-euglycemic clamp at baseline and 
after 12 weeks. Liver fat content was measured using 
magnetic resonance spectroscopy (for details see Otten 
et  al. (23)). Of the participants that provided measures 
of GC metabolism, liver fat content was measured in 14 
participants from the PD group and 11 participants from 
the PDEX group.
Excretion of glucocorticoid metabolites
The GC metabolites 5α-tetrahydrocortisol (5α-THF), 
5β-tetrahydrocortisol (5β-THF), 5β-tetrahydrocortisone 
(5β-THE), free cortisol and cortisone were measured 
in 24-h urine samples that had been stored in −80°C 
for 1–3 years, using gas chromatography tandem mass 
spectrometry (28, 29). The ratios of these GC metabolites 
were then used as indices of HSD11B1, 5α-reductase and 
5β-reductase activities as previously described (28, 29). 
In total, 12 participants from each group provided 24-h 
urine samples at baseline and 12 weeks.
Cortisone conversion test
A cortisone conversion test was used to estimate hepatic 
HSD11B1 activity. One milligram of Dexamethasone 
(Dexamethason, Galepharm, Küssnacht, Germany) was 
taken orally at 2300 h. At 0800 h the following day, a 
plasma sample was drawn and then participants took 25 
mg of cortisone acetate orally (Cortison, Nycomed Pharma, 
Asker, Norway). Blood samples were drawn every 5 min 
for 0–30 min after the cortisone dose, every 15 minute for 
30–180 min and every 13 min for 180–240 min (Fig. 1). 
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Cortisol levels were analysed (Cobas E Cortisol regency 
kits, Cobas 6000, Roche Diagnostics) immediately at 
the Department of Clinical Chemistry, Umeå University 
Hospital. Two measures were used to estimate hepatic 
HSD11B1 activity: (1.) the area under the curve for cortisol 
enrichment in plasma during the first hour after intake of 
cortisone, calculated with the trapezoidal method (AUC0–
60) and (2.) a rate-of-appearance constant (Ka) calculated 
using a one compartment model of extravascular 
administration using curve fitting. The decision of 
compensating for lag due to slow gastric emptying was 
based upon visual estimation of the best curve fit (Kinetica 
Software, Thermo Fisher, Hemel Hempsted, UK). Fourteen 
participants in the PD group and 11 participants in the 
PDEX group participated in the cortisone conversion tests 
at baseline and after 12 weeks. Due to poor curve fitting 
at baseline, the Ka constant could not be estimated at all 
for three subjects, while it was excluded for two others 
in the PD group. One participant in the PDEX group had 
forgotten to take dexamethasone prior to the test and was 
therefore excluded.
Expression of HSD11B1 transcript in subcutaneous 
adipose tissue
Expression of HSD11B1 was analysed in periumbilical 
s.c. adipose tissue. A needle biopsy was taken under local 
anesthesia, washed in saline and stored in −80°C for 1–2 
years until analysis. Real-time quantitative PCR was used 
to analyze the abundance of HSD11B1 mRNA. RNA was 
extracted using the RNeasy lipid tissue mini kit (Qiagen 
GmbH), and RNA concentrations were measured with a 
spectrophotometer (ND-1000, NanoDrop Technologies, 
Wilmington, DE, USA). Two micrograms of RNA were 
reverse transcribed using High Capacity cDNA RT kit 
(Applied Biosystems). Relative quantification real-time 
PCR was carried out using an ABI Prism 7000 Sequence 
Detection System or 7900HF Fast Real-time PCR (Applied 
Biosystems) using TaqMan Universal PCR Master Mix 2X 
(Applied Biosystems) and TaqMan Gene expression assays 
for the target gene HSD11B1 (assay no. Hs01047362_
m1, Applied Biosystems) and the endogenous control 
lipoprotein receptor-related protein 10 (LRP10, assay no 
Hs01047362_m1, Applied Biosystems). All reactions were 
performed in duplicate. Data were normalized against 
LRP10 and the comparative CT method (ΔΔCT) used for 
relative quantification of HSD11B1 gene expression. S.c. 
adipose tissue biopsies were taken from 11 participants in 
the PD group and 12 participants in the PDEX group at 
both time points.
Statistical analysis
The Kruskal–Wallis test and visual inspection of Q-Q 
plots were used to assess normal distribution. The 
measures of tissue-specific GC metabolism that were not 
normally distributed were logarithmically transformed 
before statistical analysis. All data are presented as the 
A
B
D
C
Figure 1
Results from the cortisone conversion test and excretion of GC 
metabolites to estimate hepatic HSD11B1 activity. (A) Mean 
(s.e.m.) plasma cortisol levels during 4 h after orally administered 
cortisone acetate. Paleolithic type diet (PD) at baseline = dashed 
line with circles, 12 weeks = dashed line with triangles. 
Paleolithic type diet with structured exercise (PDEX) at 
baseline = line with squares, 12 weeks = line with triangles.  
(B) Median (IQR) area under the curve from 0 to 60 min 
(AUC0–60) during the cortisone conversion test (PD n = 14, PDEX 
n = 10). (C) Median (IQR) Ka constant calculated using curve 
fitting without compensation for lag (PD n = 9, PDEX n = 10).  
(D) The ratio of 5β-THF and 5β-THF to THE, an indirect measure 
of systemic HSD11B1 activity. Black bars = PD, white bars = PDEX. 
*P < 0.05, **P < 0.01 for effect of time. #P < 0.05, ##P < 0.01 for 
effect of group. There were no significant group × time 
interactions.
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median (interquartile range (IQR)). A two-way ANOVA 
was used to test for the effect of group, time and the 
time × group interaction. The effect of group tests for 
group differences at baseline or 12 weeks, effect of time 
tests for differences between baseline and 12 weeks in 
both groups and the time × group interaction tests for 
group differences in the effect from baseline to 12 weeks 
were observed. Expression of HSD11B1 in s.c. adipose 
tissue and total excretion of urinary GC metabolites were 
significantly higher among men than women (P < 0.05) 
and therefore gender was included as a covariate for 
analyses including these measures. Spearman’s rank 
correlation coefficient was used to test correlations 
between measures of tissue-specific GC metabolism 
with BMI, waist circumference, body fat, fasting glucose, 
HbA1c, hepatic and peripheral insulin sensitivity and 
liver fat at baseline as well as changes in these measures 
during the interventions. In total, 48 correlational 
analyses were performed and the Bonferroni–Holm 
method was used as control for the family-wise error 
rate (30). A P value of < 0.05 was considered significant 
in all analyses.
Results
Participant characteristics
The main results from this intervention have been 
published previously (22, 23). This sub-study included 15 
participants in the PD group and 13 participants from the 
PDEX group that provided any measure of GC metabolism 
(either 24-h urinary samples, s.c. adipose tissue biopsies 
or completed cortisone conversion tests) at both baseline 
and after 12 weeks. The median age was 61 years and the 
median diabetes duration was 3 years. All participants 
were treated with life-style modification and 68% were 
treated with metformin. The participants were relatively 
well controlled with respect to blood glucose levels with 
a median HbA1c of 55 mmol/mol at inclusion. None of 
these characteristics were different between groups except 
for fasting blood glucose, which was significantly higher 
in the PDEX group compared to the PD group at baseline 
(Table 1, P < 0.05 for effect of group).
Diet and exercise adherence
As expected with given dietary recommendations, both 
groups reported a reduced intake of carbohydrates 
(PD: −24%; PDEX: −38%; effect of time P < 0.001) and 
saturated fatty acids (PD: −34%; PDEX: −31%, effect of 
time P < 0.001) and increased intake of protein (PD: 41%; 
PDEX: 39%; effect of time P < 0.001), monounsaturated 
(PD: 33%; PDEX: 83%; effect of time P < 0.001) and 
polyunsaturated fatty acids (PD: 60%; PDEX: 80%, effect 
of time P < 0.001). There were no significant effects 
of group or group × time interactions in the reported 
macronutrient intake. These data are presented in Table 
2.
All participants in the PDEX group completed 
>75% of all exercise sessions. In the sub-sample included 
in this study of GC metabolism, peak oxygen uptake 
increased in both groups (Table 2; PD: 8%; PDEX: 26%, 
effect of time P < 0.01) without a significant group × time 
interaction. For further details regarding exercise 
adherence see Otten et al. (22).
Intervention effects on anthropometric measures, 
body composition and insulin sensitivity
Both interventions were associated with a reduction in 
BMI (PD: −8%; PDEX: −7%; effect of time P < 0.05) and 
waist circumference (PD: −10%; PDEX: −8%; effect of 
time P < 0.05). Fasting glucose levels (PD: −19%; PDEX: 
−33%; effect of time P < 0.01) and HbA1c (PD: −21%; 
PDEX: −23%; effect of time P < 0.01) decreased in both 
groups. The suppression of hepatic glucose production 
during the hyperinsulinemic-euglycemic clamp tended 
to increase in both groups (PD: 21; PDEX: 17%, effect of 
time P = 0.093), as did the rate of glucose disappearance 
(PD: 53%; PDEX: 35%, effect of time P < 0.05), indicating 
improved hepatic and peripheral insulin sensitivity. Liver 
fat decreased in both groups (effect of time P < 0.01) 
(23). These data are presented in Table 1. There were no 
significant group × time interactions indicating similar 
effects in both groups.
Hepatic HSD11B1 activity
The rise in concentration of plasma cortisol after oral 
cortisone was significantly lower in the PD group 
at baseline (Fig. 1; AUC0–60 (PD: 15 712 nmol × h/L; 
PDEX: 22 888 nmol × h/L; effect of group P < 0.001), 
Ka (PD: 0.015; PDEX: 0.041; effect of group P = 0.13)). 
AUC0–60 and Ka increased after the intervention in 
both groups (Fig. 1, AUC0–60 effect of time P < 0.01; 
Ka effect of time P < 0.05). There were no significant 
group × time interactions indicating similar responses 
in both groups.
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Glucocorticoid metabolites in urine and 
expression of HSD11B1 in adipose tissue
The ratio of 5α-THF+5β-THF/THE, reflecting systemic 
HSD11B1 activity, increased in both groups following 
intervention (Fig. 1D and Table 3, effect of time P < 0.05). 
Otherwise, excretion of urinary GC metabolites and indices 
of 5α- and 5β-reductases were unaltered. Expression of 
HSD11B1 in adipose tissue was unaltered in both groups. 
There were no significant group × time interactions.
Associations between tissue-specific 
glucocorticoid measures and anthropometric and 
biochemical measures
Before correction for multiple comparisons, a higher 
HbA1c level was associated with higher expression of 
HSD11B1 in s.c. adipose tissue and increased excretion of 
urinary GCs (Table 4). Moreover, liver fat was associated 
with lower total excretion of GC metabolites and 
higher estimated hepatic HSD11B1 activity measured by 
AUC0–60 for the rise in plasma cortisol concentration 
after oral cortisone (Fig. 2 and Table 4). After correction 
for multiple comparisons, the association between the 
HbA1c level and total excretion of urinary GCs remained 
significant.
There were no significant associations between 
anthropometry, body fat and hepatic or peripheral 
insulin sensitivity with other indices of GC metabolism 
(Table 4).
Despite these correlations at baseline, there were 
no significant correlations between changes in these 
measures during the interventions.
Discussion
Our 12-week lifestyle interventions including a 
Paleolithic type diet with or without structured high-
intensity exercise were associated with substantial 
weight loss and improvements in insulin sensitivity. 
Furthermore, the concentration of plasma cortisol after 
a single dose of cortisone, reflecting hepatic HSD11B1 
activity, as well as the ratio of 5α-THF+5β-THF)/THE, 
Table 1 Baseline characteristics and intervention effects. Data are presented as medians (IQR).
PD PDEX
Baseline 12 weeks Baseline 12 weeks
Gender (men/women) 10/5 8/5
Age (years) 60 (11) 61 (8)
Treated with metformin (yes/no) 10/5 9/4
BMI (kg/m2) 31.4 (4.3) 28.9 (3.6)* 31.4 (6.1) 29.1 (6.7)*
Waist circumference (cm) 111 (12) 100 (18.4)* 107 (13) 99 (17.2)*
Body fat (%) 37.8 (9.2) 34.6 (9.4) 37.1 (9.8) 32.4 (11.5)
HbA1c (mmol/L) 53 (9) 42 (3)** 56 (16) 43 (5)**
Fasting glucose (mmol/L) 7.8 (1.5)# 6.3 (1.5)** 9.2 (3.4)# 7.1 (1.4)**
Suppression of hepatic glucose production (%) 89 (41) 108 (56) 108 (51) 126 (35)
Rate of glucose disappearance (mg/kg/min) 3.4 (1.3) 5.2 (3.2)* 4.0 (2.3) 5.4 (2.5)*
Liver fat (%) 22 (20) 5 (11)** 14 (19) 10 (22)**
*P < 0.05, **P < 0.01 for effect of time. #P < 0.05, ##P < 0.01 for effect of group. There were no significant group × time interactions.
PD, Paleolithic diet; PDEX, Paleolithic diet with structured exercise.
Table 2 Adherence to interventions. Data are presented as medians (IQR).
PD PDEX
Baseline 12 weeks Baseline 12 weeks
Energy intake (kCal/day) 2022 (754) 1585 (894)** 1624 (871) 1316 (510)**
Carbohydrate intake (E%) 40 (10) 31 (16)*** 45 (16) 28 (6)***
Protein intake (E%) 17 (5) 24 (10)*** 18 (4) 25 (8)***
Total fat intake (E%) 39 (4) 42 (14) 32 (6) 44 (12)
Saturated fatty acid intake (E%) 15 (4) 10 (4)*** 13 (4) 9 (2)***
Monounsaturated fatty acid intake (E%) 15 (3) 20 (10)*** 12 (5) 22 (7)***
Polyunsaturated fatty acid intake (E%) 5 (2) 8 (3)*** 5 (2) 9 (4)***
Peak oxygen uptake (ml/min/kg) 23.4 (6.4) 24.5 (7.4)** 22.8 (6.5) 28.7 (7.6)**
**P < 0.01, ***P < 0.001 for effect of time. There were no significant effects of group or group × time interactions.
E%, energy per cent; PD, Paleolithic diet; PDEX, Paleolithic diet with structured exercise.
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reflecting systemic HSD11B1 activity, increased in both 
groups. There were no significant group differences in 
these effects.
The first aim with this study was to test the association 
between anthropometric measures, glucose control, 
insulin sensitivity and liver fat with tissue specific GC 
metabolism. Notably, liver fat was a predictor of both 
lower conversion of oral cortisone to plasma cortisol 
and increased excretion of urinary GC metabolites. This 
contrasts findings in obese individuals without type 
2 diabetes in which liver fat was not associated with 
lower cortisone conversion, but increased excretion of 
5β-reduced GC metabolites (13).
Poor glucose control, indicated by a high HbA1c, was 
associated with increased excretion of GC metabolites 
as well as increased expression of HSD11B1 in s.c. 
adipose tissue. Notably, among women with impaired 
glucose tolerance, the mean glucose level during an oral 
glucose tolerance test has been associated with higher 
expression of s.c. HSD11B1 as well (31). We did not find 
any associations between either hepatic or peripheral 
insulin sensitivity measured with the hyperinsulinemic-
euglycemic clamp technique and any indices of tissue-
specific GC metabolism. Previous studies have suggested 
that a relative insulin deficiency in type 2 diabetes may be 
the cause of sustained hepatic HSD11B1 activity compared 
Table 3 Measures of tissue-specific glucocorticoid metabolism. Data are presented as medians (IQR).
PD PDEX
Baseline 12 weeks Baseline 12 weeks
5β-THF (mg/24 h) 3.3 (1.2) 2.9 (2.1) 3.1 (1.6) 3.3 (2.6)
5α-THF (mg/24 h) 3.2 (1.9) 3.7 (2.2) 3.5 (3.5) 4.3 (4.7)
THE (mg/24 h) 7.3 (4.5) 6.0 (7.1) 5.6 (2.8) 6.6 (4.2)
F (mg/24 h) 0.2 (0.1) 0.2 (0.2) 0.2 (0.1) 0.2 (0.1)
E (mg/24 h) 0.2 (0.1) 0.2 (0.2) 0.2 (0.1) 0.2 (0.1)
Total GC excretion (mg/24 h) 14.3 (7.3) 12.6 (11.9) 12.6 (6.1) 12.2 (12.3)
(5α-THF+5β-THF)/THE 0.85 (0.22) 0.98 (1.10)* 1.06 (0.57) 1.32 (1.13)*
5α-THF/F 14.06 (6.86) 15.73 (12.71) 16.25 (11.18) 22.8 (11.65)
5α-THF/5β-THF 0.98 (0.36) 1.19 (1.24) 0.93 (0.97) 1.30 (0.70)
THF/F 14.22 (8.06) 11.53 (7.20) 15.61 (6.35) 17.25 (13.69)
THE/E 35.70 (15.16) 27.04 (27.11) 29.92 (9.13) 30.15 (13.83)
F/E 1.02 (0.34) 1.06 (0.34) 1.04 (0.16) 0.92 (0.54)
HSD11B1 expression (AU) 12.15 (9.59) 14.45 (7.47) 14.48 (9.02) 12.76 (9.33)
AUC0–60 (μmol × h/L) 15.7 (5.2)## 22.4 (11.3)** 22.8 (14.1)## 25.9 (4.4)**
Ka 0.015 (0.01) 0.052 (0.07)* 0.041 (0.06) 0.039 (0.08)*
CBG (nmol/L) 742 (146)## 726 (60) 856 (159)## 801 (114)
*P < 0.05, **P < 0.01 for effect of time. #P < 0.05, ##P < 0.01 for effect of group. There were no significant group × time interactions.
5α-THF, 5α-tetrahydrocortisol; 5β-THF, 5β-tetrahydrocortisol; CBG, Cortisol binding globulin; E, cortisone; F, cortisol; PD, Paleolithic diet; PDEX, Paleolithic 
diet with structured exercise; THE, tetrahydrocortisone; total GC excretion, the sum of all measured glucocorticoid metabolites.
Table 4 Associations between measures of tissue specific glucocorticoid metabolism and anthropometry, body fat, glucose 
control, insulin sensitivity and liver fat at baseline. The hyperinsulinemic–-euglycemic clamp was used to estimate hepatic insulin 
sensitivity as the suppression of hepatic glucose production and peripheral insulin sensitivity as the rate of glucose 
disappearance. Spearman rank correlations were used for cortisone conversion and partial correlations corrected for gender for 
HSD11B1 and urinary glucocorticoid metabolites.
BMI WC Body fat HbA1c fP-glucose HIS PIS Liver fat
Cortisone conversion (AUC0–60) −0.1 −0.35 0.13 0.002 0.35 −0.058 0.30 −0.48 
 n 25 25 25 25 24 19 19 22
 P 0.6 0.09 0.5 0.9 0.09 0.8 0.2 0.03
Expression of HSD11B1 in s.c. adipose tissue 0.028 0.063 0.19 0.43 0.35 −0.053 0.10 0.41 
 n 23 23 23 23 20 19 19 17
 P 0.9 0.8 0.4 0.04 0.1 0.8 0.7 0.08
Total excretion of urinary glucocorticoid metabolites −0.016 0.056 0.012 0.63 0.60 −0.32 −0.24 0.63
 n 24 24 24 24 23 19 19 21
 P 0.9 0.8 0.9 0.001 0.003 0.2 0.3 0.003
 WC, waist circumference; HIS, hepatic insulin sensitivity; PIS, peripheral insulin sensitivity.
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to obese individuals without type 2 diabetes (6, 12). Thus, 
we hypothesized that a higher degree of insulin resistance 
would be associated with increased hepatic HSD11B1 
activity. One reason for these unexpected results may be 
that all participants in this study had type 2 diabetes and 
that the effects of insulin resistance may be more evident 
in a group of patients with a larger variance in insulin 
resistance. The rather small study groups may also have 
limited the possibility to find significant associations 
between insulin resistance and HC metabolism.
Previous studies in non-diabetic obese individuals 
have found a clear association between BMI and waist 
circumference with excretion of GC metabolites in urine 
(4, 32, 33, 34). Surprisingly, this association was not evident 
in this group of type 2 diabetes patients. To summarize, 
our results suggest that liver fat, rather than the degree of 
insulin resistance or obesity, influences hepatic HSD11B1 
activity and GC metabolism. This should be further tested 
in larger samples of type 2 diabetes patients, since these 
associations did not remain significant after correction for 
multiple testing.
The second and third aim of the study was to test 
the effect of diet-induced weight loss with improved 
insulin sensitivity on tissue-specific GC metabolism and 
whether these effects are modified by intensive exercise. 
Previously, we have shown that a 2-year intervention with 
a PD associated with a 5–10% weight reduction increased 
the systemic activity of 5α-reductase and reduced the 
expression of HSD11B1 in s.c. adipose tissue among obese 
women without type 2 diabetes (18). These results were 
not replicated in this shorter intervention among patients 
with type 2 diabetes. One reason for these discrepant 
results may be that an intervention longer than 12 
weeks is needed to induce changes in GC metabolism. 
Furthermore, type 2 diabetes may also alter the effects of 
lifestyle interventions on tissue-specific GC metabolism 
compared to lifestyle changes among obese patients with 
normal insulin sensitivity.
The concentration of plasma cortisol after oral 
cortisone increased significantly after the interventions 
without a significant group difference. Numerically, the 
increase was greater in the PD compared with the PDEX 
group. However, since the cortisone conversion was 
significantly higher in the PDEX group compared to the 
PD group at baseline, probably caused by higher CBG 
levels (35) (Table 3), no firm conclusion can be drawn as 
to whether this tendency of group difference was due to 
a moderating effect of exercise training or the baseline 
difference per se. However, we have previously reported 
that exercise attenuated the loss of hepatic lipid content on 
a PD (23). Since higher liver fat was associated with lower 
cortisone conversion at baseline, it cannot be excluded 
that the addition of exercise also led to a reduced effect 
on hepatic HSD11B1 activity based on the attenuated 
reduction of liver fat.
The rise in plasma cortisol concentration after oral 
cortisone depends both on the metabolic clearance rate 
of GCs, as well as the conversion of cortisone to cortisol 
by HSD11B1 in the liver (8). Excretion of urinary GC 
metabolites was unaltered in both groups suggesting an 
unaltered metabolic clearance rate. On the other hand, the 
ratio of cortisol to cortisone metabolites ((5αTHF + 5βTHF)/
THE) in urine, considered to reflect systemic HSD11B1 
activity (28), increased in both groups. These findings 
support the hypothesis that the increased concentration of 
plasma cortisol after oral cortisone was caused by increased 
hepatic HSD11B1 activity. Future studies could use tracer 
techniques to further elucidate these potential alterations 
in hepatic HSD11B1 activity after weight loss (6).
The level of hepatic lipid content is a potential 
modifier of hepatic GC metabolism (13, 14, 36). It has 
been suggested that steatosis is associated with decreased 
conversion of cortisone to cortisol by hepatic HSD11B1, 
whereas steatohepatitis might lead to increased 
conversion (13, 14). In our study, a higher hepatic lipid 
content was associated with increased excretion of GC 
metabolites in urine and lower plasma cortisol after the 
cortisone conversion test at baseline. This may indicate 
that the reduction of hepatic lipid content during the 
interventions caused a reduced clearance rate of GCs and 
thereby increased concentration of plasma cortisol after 
Figure 2
Area under the curve (AUC0–60) for plasma cortisol levels 60 
min after a dose of orally taken cortisone was associated with 
hepatic lipid content at baseline. Dots represent the Paleolithic 
diet group and squares Paleolithic diet with exercise.
Downloaded from Bioscientifica.com at 03/25/2020 10:12:16AM
via University of Edinburgh
Eu
ro
pe
an
 Jo
ur
na
l o
f E
nd
oc
ri
no
lo
gy
182:4 455Clinical Study A Stomby and others Glucocorticoid metabolism in 
type 2 diabetes
https://eje.bioscientifica.com
the cortisone conversion test. However, it should be noted 
that there were no significant correlations between changes 
in these measures throughout the interventions and the 
ratio of cortisol to cortisone metabolites (5αTHF + 5βTHF/
THE) in urine, reflecting systemic HSD11B1 activity (28), 
was not correlated to hepatic lipid content. Moreover, a 
high-fat-low-carb diet with a carbohydrate intake as low 
as 4% has been suggested to increase systemic HSD11B1 
activity, measured with a tracer technique, independently 
of weight-loss in obese non-diabetic males (37). The 
participants in our study reported an intake of about 
30% carbohydrates. Thus, the altered macronutrient 
composition could play a part in the increased hepatic 
HSD11B1 activity, but is unlikely to be the sole contributor 
to these alterations.
Recently, metformin was shown to increase hepatic 
HSD11B1 activity in subjects with type 2 diabetes, an effect 
likely linked to increased insulin sensitivity (38). We did 
not find any significant associations between estimated 
hepatic HSD11B1 and neither peripheral nor hepatic 
insulin sensitivity measured with the hyperinsulinemic-
euglycemic clamp technique. The cortisone conversion 
test is a less specific and sensitive test to estimate the 
hepatic HSD11B1 activity compared with the more 
recently developed tracer techniques (5, 38). This may, at 
least in part, explain these different findings.
Using indirect measures to estimate tissue-specific 
GC metabolism has limitations (8). As discussed, it is 
not always straightforward to infer mechanistic tissue-
specific changes in GC metabolism by using these indirect 
measurements. Using tracer techniques and hepatic vein 
catheterization, would ultimately provide more specific 
and sensitive estimates of hepatic HSD11B1 activity (5). 
Our sample size was fairly small with a limited power to 
detect significant effects which may have affected some 
of our results. Some participants who took part in the 
interventions did not take part in measures of tissue-
specific GC metabolism at both baseline and 12 weeks 
and were therefore excluded. The specific reason for 
not taking part was not documented. The PDEX group 
reported a non-significant lower total intake of calories 
at baseline and after 12 weeks than the PD group. 
However, all participants reported stable weight for the 
last 6 months, and the reduction in weight and waist 
circumference during the interventions were similar. 
This difference is likely an effect of underreported 
calorie intake rather than actual differences, which is 
common with self-reported food intake. Those treated 
with metformin had a significantly higher BMI, HbA1c 
and more insulin resistance (data not shown) compared 
to those treated with life-style modification. This limited 
the possibility to test the effects of metformin, which 
could have been relevant with respect to previous studies 
(38). There was a large variance in hepatic lipid content 
and hepatic insulin sensitivity within and between 
groups at baseline. Although these differences were 
not statistically significant, they may have influenced 
the effects of the interventions. We tested several 
associations between measures of GC metabolism and 
anthropometry, insulin sensitivity and liver fat. These 
tests were based on hypotheses from previous studies, but 
after correction for multiple testing, several associations 
did not remain significant. All women included were 
postmenopausal, so we cannot say if other associations/
responses are present in premenopausal women, as 
suggested by earlier studies (26).
To conclude, intervention with a PD was associated 
with increased cortisone conversion, reflecting increased 
hepatic HSD11B1 activity. Adding exercise to a PD did not 
have a significant impact on these effects.
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